MMP9 and cancer: To determine if inhibiting this novel CB1 GPCR signaling platform affects cell viability and metabolic activity, the cancer cells were treated with the NMBR inhibitor BIM-23127 (BIM-23), MMP-9 inhibitor I (MMP9-i), a potent reversibly selective inhibitor of MMP-9, and oseltamivir phosphate (OP), a broad range neuraminidase sialidase inhibitor, for 15 min, followed by the synthetic cannabinoids.